Author:
Jovanovic-Cupic Snezana,Bozovic Ana,Krajnovic Milena,Petrovic Nina
Reference119 articles.
1. World Health Organization. Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection. 2016. Available from: http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf (Accessed March 6, 2018)
2. Poynard T, Yuen M-F, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095-2100
3. Perz JF, Alter MJ. The coming wave of HCV-related liver disease: Dilemmas and challenges. Journal of Hepatology. 2006;44(3):441. DOI: 10.1016/j.jhep.2005.12.007
4. Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, et al. Poor sustained virological response in a Multicenter real-life cohort of chronic hepatitis C patients treated with Pegylated interferon and ribavirin plus telaprevir or boceprevir. Digestive Diseases and Sciences. 2015;60:1045-1051. DOI: 10.1007/s10620-015-3621-0
5. Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology. 2016;65:S2-S21. DOI: 10.1016/j.jhep.2016.07.035